Ardelyx Reports China’s NMPA Approval of Tenapanor for Hyperphosphatemia in Patients
Shots:
- China’s NMPA has approved NDA of tenapanor for hyperphosphatemia in CKD pts on dialysis who inadequately responded or are intolerant to phosphorus binders
- Approval was based on data from 2 Fosun Pharma studies (PK study & pivotal trial in CKD pts on dialysis), plus clinical studies from Ardelyx
- Approval triggered $5M milestone payment to Ardelyx under its licensing deal with Fosun Pharma, that granted Fosun exclusive rights to market tenapanor (chinese trade name: Wan Ti Le) in China, Hong Kong, & Macau, in exchange for ~$100M in development & commercialization milestones, plus net sales-based tiered royalties from mid-teens to 20%
Ref: Globenewswire | Image: Ardelyx
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
